Dear Colleagues,

Although the diagnosis of diffuse gliomas has been historically based on histopathologic features, our knowledge of the genetic and epigenetic landscape has dramatically improved over the past decade. Key genomic alterations defining glioma subtypes are now part of the routine molecular diagnostic workout, allowing a better stratification of patients' prognosis, and guiding decision making with regard to treatment. Nowadays, it has also become clear that the glioma tumor microenvironment (TME) plays as a critical role in cancer development and progression. The unique and highly complex properties of the brain require a specific deep analysis of both the cellular and non-cellular TME components for a better understanding of how gliomas escape from immunosurveillance and to design targeted therapeutic interventions harnessing the TME to fight cancer. Unfortunately, these great advances in the molecular and immunological characterization of diffuse gliomas have not yet led to significant changes in the treatment paradigms and in the prognosis of patients, which generally remains poor. This Special Issue of Cancers aims to explore emerging insights on the molecular landscape, the immunological milieu and therapeutic management of diffuse gliomas. Our purpose is to focus on most recent technologies able to address gliomas’ inter-tumoral and intra-tumoral genetic and epigenetic heterogeneity with an unprecedented resolution, on novel diagnostic techniques such as liquid biopsies, radiomics, or advanced imaging, allowing non-invasive molecular diagnosis and surveillance, and finally on the discovery of novel “druggable” targets and therapeutic strategies for the treatment of diffuse gliomas.

We cordially invite you to contribute to this Special Issue of Cancers with your latest original research within this scope. Expert perspectives, comprehensive reviews, and meta-analyses are also welcome.

We look forward to receiving your contributions.

Dr. Matteo Simonelli
Prof. Dr. Federico Pessina
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• diffuse gliomas
• glioblastoma
• neuro-oncology
• neurosurgery
• radiomics
• liquid biopsies
• immunotherapy
• epigenetics
• targeted therapy
• imaging